Cytokinetics, Incorporated (NASDAQ:CYTK) Stock Holdings Lifted by Checkpoint Capital L.P.

Checkpoint Capital L.P. raised its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 145.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 466,813 shares of the biopharmaceutical company’s stock after buying an additional 276,813 shares during the quarter. Cytokinetics comprises about 12.2% of Checkpoint Capital L.P.’s portfolio, making the stock its 4th biggest holding. Checkpoint Capital L.P. owned approximately 0.40% of Cytokinetics worth $24,648,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in CYTK. J.Safra Asset Management Corp boosted its holdings in Cytokinetics by 642.3% during the 2nd quarter. J.Safra Asset Management Corp now owns 527 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 456 shares during the period. UMB Bank n.a. boosted its stake in shares of Cytokinetics by 65.6% during the third quarter. UMB Bank n.a. now owns 601 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 238 shares during the period. Blue Trust Inc. lifted its holdings in shares of Cytokinetics by 225.9% during the third quarter. Blue Trust Inc. now owns 981 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 680 shares during the period. Values First Advisors Inc. purchased a new stake in shares of Cytokinetics in the third quarter valued at about $54,000. Finally, Quarry LP increased its position in Cytokinetics by 233.3% during the 2nd quarter. Quarry LP now owns 2,000 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 1,400 shares during the period.

Insider Buying and Selling

In related news, CEO Robert I. Blum sold 5,000 shares of Cytokinetics stock in a transaction on Monday, November 18th. The shares were sold at an average price of $50.55, for a total transaction of $252,750.00. Following the transaction, the chief executive officer now owns 397,456 shares in the company, valued at approximately $20,091,400.80. The trade was a 1.24 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Fady Ibraham Malik sold 7,300 shares of the stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $50.16, for a total value of $366,168.00. Following the completion of the sale, the executive vice president now owns 111,878 shares of the company’s stock, valued at approximately $5,611,800.48. This represents a 6.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 72,378 shares of company stock valued at $3,880,287. 3.40% of the stock is currently owned by corporate insiders.

Cytokinetics Trading Down 0.7 %

Shares of CYTK opened at $51.86 on Monday. Cytokinetics, Incorporated has a twelve month low of $32.35 and a twelve month high of $110.25. The firm has a market capitalization of $6.12 billion, a P/E ratio of -9.64 and a beta of 0.78. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 5.93. The stock’s fifty day simple moving average is $53.21 and its 200 day simple moving average is $54.39.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($1.36) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.09). The business had revenue of $0.46 million during the quarter, compared to the consensus estimate of $1.21 million. Cytokinetics’s revenue was up 22.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.35) EPS. On average, equities research analysts forecast that Cytokinetics, Incorporated will post -5.25 earnings per share for the current year.

Analyst Ratings Changes

CYTK has been the subject of a number of research analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $72.00 price target on shares of Cytokinetics in a report on Wednesday, November 20th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Cytokinetics in a research note on Friday, October 18th. HC Wainwright restated a “buy” rating and issued a $120.00 target price on shares of Cytokinetics in a report on Monday, November 18th. JPMorgan Chase & Co. raised their price target on shares of Cytokinetics from $65.00 to $71.00 and gave the stock an “overweight” rating in a research note on Thursday, September 5th. Finally, The Goldman Sachs Group lowered shares of Cytokinetics from a “buy” rating to a “neutral” rating and cut their price objective for the company from $85.00 to $60.00 in a research report on Tuesday, August 13th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $83.93.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.